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Livers	from	controlled	donation	after	circulatory	death	(DCD)	donors	suffer	a	higher	
incidence	of	nonfunction,	poor	function,	and	ischemic	cholangiopathy.	In	situ	normo‐
thermic	regional	perfusion	 (NRP)	restores	a	blood	supply	to	the	abdominal	organs	
after	death	using	an	extracorporeal	circulation	for	a	limited	period	before	organ	re‐
covery.	We	undertook	a	retrospective	analysis	to	evaluate	whether	NRP	was	associ‐
ated	with	improved	outcomes	of	livers	from	DCD	donors.	NRP	was	performed	on	70	
DCD	donors	from	whom	43	livers	were	transplanted.	These	were	compared	with	187	
non‐NRP	DCD	donor	 livers	 transplanted	at	 the	same	two	UK	centers	 in	 the	same	
period.	The	use	of	NRP	was	associated	with	a	reduction	in	early	allograft	dysfunction	
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1  | INTRODUCTION
The	success	of	liver	transplantation	as	a	treatment	for	patients	with	
liver	disease	is	limited	by	a	shortage	of	suitable	donor	organs,	such	
that	of	those	patients	listed	for	a	liver	transplant	in	2014	and	2015	in	
the	UK,	13%	died	and	8%	were	removed	from	the	list	within	2	years	
without	undergoing	liver	transplantation.1	The	situation	is	similar	in	
the	United	States	where	12%	of	patients	listed	in	2013	died	and	17%	
were	 removed	 from	 the	 list	 in	 the	 subsequent	 2	years.2	 This	 high	
waiting	list	attrition	has	led	surgeons	to	use	organs	that	were	previ‐
ously	considered	to	be	at	higher	risk	of	failure,3	balancing	the	risk	of	
death	without	a	transplant	against	the	risk	of	complications	from	a	
suboptimal	graft.4	Livers	donated	after	circulatory	death	(DCD)	are	
one	such	higher	risk	category.
Following	 withdrawal	 of	 life‐supporting	 treatment	 in	 a	 potential	
DCD	 donor,	 the	 autonomic	 response	 to	 falling	 cerebral	 perfusion	 is	
characterized	by	 release	of	catecholamines	which	cause	an	alpha‐ad‐
renergic	mediated	peripheral	and	mesenteric	vasoconstriction,	resulting	
in	reduced	blood	flow	to	the	liver.5,6	Hence	during	the	withdrawal	pe‐
riod	before	circulatory	arrest	the	liver	suffers	significant	ischemia.	This	is	
then	compounded	by	a	further	period	of	warm	ischemia	after	circulatory	
arrest	(the	asystolic	period)	during	which	the	donor	is	verified	dead	and	
is	transferred	to	the	operating	room	where,	following	a	rapid	 laparot‐
omy,	the	organs	are	flushed	and	cooled	in	situ	with	preservation	fluid.	
Cold	perfusion	reduces,	but	does	not	stop	the	metabolic	processes	that	
were	active	in	the	warm,	and	leads	to	further	depletion	of	high	energy	
phosphates	that	occurs	rapidly	during	warm	ischemia.	The	successive	
insults	of	warm	ischemia	followed	by	cold	storage	account	for	the	sub‐
optimal	nature	of	 livers	donated	after	circulatory	death	(DCD),	with	a	
higher	incidence	of	primary	nonfunction	and	initial	poor	function	com‐
pared	to	those	from	brain	dead	donors.	In	addition,	DCD	donor	livers	
are	associated	with	a	higher	 incidence	of	biliary	complications	and	 in	
particular	nonanastomotic	biliary	strictures	(“ischemic	cholangiopathy”)	
which	can	be	seen	in	20%	to	30%	of	DCD	livers.7,8	DCD	donors	com‐
prise	41%	of	deceased	donors	in	the	UK,	and	17%	in	the	United	States.1,2 
The	high	proportion	of	DCD	donors	has	forced	increasing	utilization	of	
DCD	donor	livers	to	address	the	waiting	list	mortality,	such	that	24%	of	
transplanted	livers	in	the	UK	in	2016	and	2017	were	from	DCD	donors;	
this	compares	to	just	6%	in	the	United	States	in	2016.1,2,9
In	 situ	 normothermic	 regional	 perfusion	 is	 a	 technique	 that	 re‐
stores	a	circulation	of	oxygenated	blood	to	the	abdominal	organs	via	
cannulas	 in	 the	aorta	and	vena	cava	using	an	extracorporeal	circuit	
containing	a	membrane	oxygenator,	heater,	and	pump.	Restoration	of	
a	blood	supply	arrests	the	ischemic	damage	to	the	liver	and	allows	it	to	
recover	before	being	cooled	down	for	transport	to	the	recipient	cen‐
ter.	In	this	way,	it	converts	DCD	donation	into	a	situation	more	akin	
to	that	seen	in	DBD	donation.	In	an	effort	to	improve	the	outcomes	
of	DCD	liver	transplantation,	we	started	a	program	of	normothermic	
regional	perfusion	(NRP)	in	two	UK	centers	in	2011	and	2012.10,11
Several	 groups	 have	 described	 encouraging	 outcomes	 of	DCD	
organ	transplantation	following	NRP,12‐14	 initially	with	kidneys	but,	
latterly,	cases	of	successful	liver	transplantation.15‐19	Originally	pio‐
neered	in	uncontrolled	DCD	donation	in	Spain	and	Taiwan,20,21	NRP	
is	 increasingly	 used	 for	 controlled	DCD	donation	 in	 Spain,	 France	
and	the	UK.11,19,22	In	contrast	to	Spain	and	France,	where	premortem	
cannulation	and	heparinization	are	permitted,	current	guidance	does	
not	permit	either	in	the	UK.
This	paper	describes	 the	experience	of	 the	two	pioneering	UK	
centers	with	the	use	of	NRP	for	DCD	liver	transplantation	and	fo‐
cuses	on	the	recognized	complications	of	DCD	liver	transplantation,	
namely	 early	 allograft	 dysfunction	 and	 ischemic	 cholangiopathy.	
NRP	was	used	 in	 two	settings,	one	solely	by	the	abdominal	 trans‐
plant	team	and	the	other	 in	collaboration	with	cardiac	surgeons	to	
facilitate	heart	transplantation	from	DCD	donors.23
2  | MATERIALS AND METHODS
This	 retrospective	 study	 used	 prospectively	 collected	 data	 collated	
from	the	UK	Transplant	Registry	and	hospital	records	on	patients	un‐
dergoing	transplantation	using	livers	recovered	from	DCD	donors	after	
a	period	of	NRP.	NRP	was	 considered	 in	donors	when	 trained	 staff	
were	available,	and	was	initially	conducted	as	part	of	an	approved	clini‐
cal	research	study	in	which	donor	families	consented	to	NRP	treatment	
(12%	for	NRP	vs.	32%	for	non‐NRP	livers,	P	=	.0076),	30‐day	graft	loss	(2%	NRP	livers	
vs.	12%	non‐NRP	 livers,	P	=	.0559),	 freedom	from	ischemic	cholangiopathy	 (0%	vs.	
27%	for	non‐NRP	 livers,	P	<	.0001),	and	 fewer	anastomotic	strictures	 (7%	vs.	27%	
non‐NRP, P	=	.0041).	After	adjusting	for	other	factors	in	a	multivariable	analysis,	NRP	
remained	 significantly	 associated	 with	 freedom	 from	 ischemic	 cholangiopathy	
(P	<	.0001).	These	data	suggest	that	NRP	during	organ	recovery	from	DCD	donors	
leads	to	superior	liver	outcomes	compared	to	conventional	organ	recovery.
K E Y WO RD S
clinical	research/practice,	donors	and	donation:	donation	after	circulatory	death	(DCD),	
extracorporeal	membrane	oxygenation	(ECMO),	liver	transplantation/hepatology,	surgical	
technique
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of	the	donor	and	the	recipients	consented	to	receive	an	organ	treated	
by	NRP.	Latterly,	NRP	has	been	performed	as	part	of	a	service	evalu‐
ation	by	 the	National	Health	Service	Blood	and	Transplant	 (NHSBT)	
organization	 in	 the	UK.	 In	 this	 latter	period,	when	 the	safety	of	 the	
technique	had	been	confirmed,	recipients	gave	consent	for	an	organ	
from	a	DCD	donor,	regardless	of	whether	the	donor	had	undergone	
NRP	or	not.	Interest	in	utilization	of	hearts	from	DCD	donors	led	to	a	
bias	in	favor	of	younger	donors	at	one	center	where	the	cardiothoracic	
teams	were	able	to	call	on	different	staff	to	perform	the	perfusions.
2.1 | Normothermic regional perfusion (NRP)
NRP	was	undertaken	in	two	contexts,	one	to	assess	and	retrieve	the	
abdominal	organs	alone	and	the	other	to	also	assess	and	recover	the	
heart	 for	 transplantation;	 the	 abdominal	 organs	 received	 the	 same	
treatment	 in	 each	 case.	 All	 donors	 were	 controlled	 DCD	 donors	
(Maastricht	 III).24	 In	all	 cases	 the	mode	of	withdrawal	of	 treatment	
was	left	to	the	intensivist	caring	for	the	patient,	but	usually	comprised	
extubation	and	discontinuation	of	inotropes.	Death	was	confirmed	no	
less	than	5	minutes	after	cessation	of	the	circulation	following	which	
the	patient	was	transferred	to	the	operating	room.	Abdominal	NRP	
(A‐NRP)	was	performed	by	cannulating	 the	aorta	or	 right	 common	
iliac	artery,	and	the	inferior	vena	cava	or	right	common	iliac	vein,	with	
an	endovascular	or	external	clamp	occluding	the	descending	thoracic	
aorta.	 Thoracoabdominal	 NRP	 (TA‐NRP)	 was	 performed	 either	 by	
cannulating	the	ascending	aorta	and	IVC	via	the	right	atrial	append‐
age,	or	cannulating	the	abdominal	aorta	and	IVC,	with	a	clamp	placed	
across	the	origins	of	the	brachiocephalic	trunk,	left	common	carotid	
and	 left	 subclavian	 arteries;	 there	was	 no	 simultaneous	 abdominal	
cannulation	in	these	cases.	Current	preference	for	DCD	heart	recov‐
ery	involves	abdominal	aortic	cannulation,	since	that	affords	better	
access	for	clamping	the	arch	vessels	to	prevent	cerebral	perfusion.
The	 prime	 solution	 comprised	 compound	 sodium	 lactate	
(Hartmann's	 solution,	Baxter	Healthcare	Ltd,	Thetford,	UK)	and	suc‐
cinylated	 gelatin	 (Gelofusine,	 BBraun),	 and	 contained	 antimicrobials,	
1	mmol/kg	sodium	bicarbonate,	and	25	000	units	heparin	as	previously	
described,10	with	additional	mannitol	and	heparin	 for	TA‐NRP.	Ante‐
mortem	cannulation	and	heparinization	are	not	permitted	in	the	UK.
The	 circuit	 comprised	 an	 oxygenator,	 heat	 exchanger,	 pump,	
and	 latterly,	 a	 leucocyte	 filter	 (LeukoGuard,	 Pall	 Corporation,	
Portsmouth,	 UK),	 either	 using	 bespoke	 cardiopulmonary	 bypass	
equipment	from	Medtronic	(Watford,	UK),	the	Cardiohelp	(Maquet,	
Sunderland,	UK),	or	the	Extra‐Corporeal	Organ	Procurement	System	
(ECOPS)	or	 the	Donor	Assist	 (both	 from	Organ	Assist,	Groningen,	
Netherlands).	Irrespective	of	the	equipment,	the	target	for	abdom‐
inal	NRP	 flow	was	2.5‐3	L/min,	with	 higher	 flow	 rates	 (4‐6	L/min)	
being	employed	for	TA‐NRP.	The	leucocyte	filter	was	excluded	from	
the	circuit	for	the	first	2	minutes	to	allow	adequate	mixing	of	blood	
with	heparin	to	minimize	the	risk	of	clot	formation.
The	intention	was	to	restore	a	circulation	to	the	abdominal	organs	
for	2	hours	before	in	situ	perfusion	with	cold	University	of	Wisconsin	
preservation	 solution.	Where	 TA‐NRP	 was	 performed	 and	 cardiac	
output	was	restored,	the	extracorporeal	perfusion	was	stopped	at	30	
to	60	minutes	and	the	heart	allowed	to	support	the	limited	thoracoab‐
dominal	 circulation	while	 its	 function	was	 evaluated.	 If	 the	 cardiac	
function	was	considered	inadequate	and	failing	to	sustain	an	adequate	
mean	arterial	pressure,	extracorporeal	perfusion	was	recommenced.
The	decision	 to	use	 the	 liver	was	based	on	 subjective	 and	bio‐
chemical	 factors.	 The	 appearance	 of	 the	 liver	 during	NRP	was	 as‐
sessed,	 with	 cirrhotic	 and	 severely	 steatotic	 livers	 being	 declined.	
Alanine	transaminase	(ALT)	was	measured	in	the	perfusate	every	30	
to	60	minutes	during	NRP.	In	our	early	experience	an	ALT	over	200	
iu/L	would	 result	 in	 the	 liver	 being	declined,	 but	 latterly	 perfusion	
ALTs	up	to	500	iu/L	have	been	accepted,	providing	there	was	no	con‐
tinued	rise	in	ALT	between	the	first	and	second	hour.	Perfusate	lactate	
concentrations	were	measured	every	30	minutes,	as	part	of	the	blood	
gas	profile	used	 to	manage	gas	delivery	 to	 the	circuit.	A	 fall	 in	 lac‐
tate	was	also	considered	encouraging,	but	deoxygenated	lactate‐rich	
blood	draining	back	into	the	circuit	from	nonperfused	areas	together	
with	the	lactate	content	in	supplementary	Hartmann's	solution	made	
this	less	reliable	as	an	indicator;	 in	later	perfusions	Hartmann's	was	
not	administered	once	NRP	had	commenced.	Typically,	the	lactate	fell	
between	3	and	14	mmol/L	over	the	2	hours	of	perfusion.
2.2 | NRP and comparator cohorts
A	 contemporaneous	 comparator	 cohort	 comprised	 all	 DCD	 liver	
transplants	 performed	 at	 both	 centers	 since	 the	 start	 of	 the	NRP	
program.	Livers	subject	to	ex	situ	machine	perfusion	were	excluded.
2.3 | Definitions
Ischemic	cholangiopathy	was	defined	as	 the	presence	of	any	non‐
anastomotic	biliary	stricture	on	endoscopic	or	magnetic	resonance	
cholangiopancreatography	 (ERCP	 or	MRCP)	 in	 the	 absence	 of	 ar‐
terial	 thrombosis	 or	 stenosis.	 Cholangiography	 was	 undertaken	
when	clinically	indicated	by	pruritus,	cholangitis,	raised	bilirubin	or	
ALP	posttransplant.	Protocol	cholangiograms	were	also	performed	
as	 part	 of	 the	 initial	 evaluation	 of	NRP.	 Patients	with	 evidence	of	
strictures	but	without	symptoms	sufficiently	severe	to	warrant	re‐
transplantation	were	treated	symptomatically,	often	with	attempts	
at	endoscopic	or	percutaneous	duct	clearance	of	any	debris.
An	anastomotic	stricture	was	defined	as	any	stricture	at	the	bil‐
iary	 anastomosis	 requiring	 treatment,	 and	anastomotic	 leaks	were	
defined	as	a	bile	 leak	confirmed	at	 laparotomy;	no	suspected	 leak	
was	managed	without	surgery	in	either	group.	Glomerular	filtration	
rate	was	calculated	using	the	Chronic	Kidney	Disease	Epidemiology	
Collaboration	(CKD‐Epi)	equation.25
Organ	damage	was	graded	separately	by	the	donor	surgeon	and	
recipient	 center	 as	 minor	 (trivial)	 or	 moderate	 (needs	 repair);	 the	
worst	degree	of	damage	reported	is	recorded	here.
2.4 | Statistical analysis
Descriptive	data	were	presented	as	median,	 interquartile	 range	or	
range	 (continuous	 variables)	 or	 number,	 percentage	 (categorical	
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variables)	and	were	compared	using	the	Kruskal‐Wallis	test	(continu‐
ous	variables)	and	Fisher's	exact	test	(categorical	variables).	Analysis	
of	variance	(ANOVA)	was	used	to	compare	CKD‐Epi	GFR	over	time	
between	 NRP	 and	 comparator	 cohorts.	 A	 random	 effect	 was	 in‐
cluded	in	the	ANOVA	model	to	allow	for	correlation	between	GFR	
results	at	different	time	points	for	the	same	patient.	Kaplan	Meier	
estimates	of	graft	survival	were	compared	using	the	 log‐rank	test.	
Graft	survival	was	defined	as	the	time	from	transplant	to	graft	failure	
with	patient	deaths	with	a	 functioning	graft	censored.	Logistic	 re‐
gression	was	used	to	determine	the	factors	associated	with	develop‐
ing	ischemic	cholangiopathy.	Analyses	were	undertaken	using	SAS/
STAT,	 version	 9.4	 (SAS	 Institute	 Inc.,	 Cary,	NC)	 and	 Prism	 version	
7.0c	(GraphPad,	La	Jolla,	CA).
3  | RESULTS
Between	 January	 1,	 2011	 and	 June	 30,	 2017,	 43	 DCD	 liver	
transplants	were	performed	from	70	DCD	donors	undergoing	NRP.	
These	 were	 compared	 with	 187	 non‐NRP	 DCD	 liver	 transplants	
performed	 over	 the	 same	 period.	Details	 of	 the	 donors	 are	 given	
in	Table	1,	as	are	details	of	 the	27	NRP	donors	whose	 livers	were	
not	used.	Reasons	 for	not	using	 livers	 included	donor	encephalitis	
of	unknown	cause	(n	=	1),	abnormal	liver	appearance	(n	=	7:	steato‐
sis	[n	=	3],	fibrosis,	cirrhosis,	trauma,	lesion),	thromboemboli	(n	=	3),	
bleeding	 (n	=	1),	 abnormal	 liver	 function	 tests	pre‐NRP	 (n	=	2),	 ris‐
ing	ALT	(n	=	5,	including	3	donors	over	70	years	old),	recipient	unfit	
perioperatively	(n	=	1)	and	prolonged	withdrawal	period	(n	=	7:	with‐
drawal	period	durations	76,	90,	90,	113,	127,	133,	and	176	minutes).	
The	liver	utilization	rates	over	time	are	shown	in	the	supplementary	
data,	Figures	S1A,B.	As	experience	accrued,	livers	from	donors	with	
longer	withdrawal	periods	and	with	higher	biochemistry	thresholds	
were	used.	There	was	no	difference	in	UK	donor	liver	index	between	
NRP	and	non‐NRP	livers,	nor	in	the	donors	where	the	livers	were	not	
used.3	The	US	donor	risk	index	for	livers	was	higher	in	the	non‐NRP	
livers	reflecting	the	longer	cold	ischemic	time	and	fewer	local	donors	
(Table	1).4,26	Of	 the	 43	 cases	where	NRP	was	 performed	 and	 the	
liver	transplanted,	TA‐NRP	was	performed	in	10	cases	from	which	9	
hearts	were	also	transplanted.
3.1 | Donor demographics and timings
The	median	donor	age	in	the	NRP	liver	transplants	was	41,	compared	
to	50	in	the	comparator	group	(Table	1).	There	was	a	greater	propor‐
tion	of	head	injury	liver	donors	undergoing	NRP	(23%	NRP	vs.	12%	
non‐NRP)	and	more	donors	dying	from	hypoxic	brain	 injury	 in	 the	
non‐NRP	comparator	 cohort	 (37%	non‐NRP,	28%	NRP),	 but	 these	
differences	were	not	significant	(P	=	.5358).	A	greater	proportion	of	
the	liver	donors	were	in	the	transplant	center	in	the	NRP	group	com‐
pared	 to	 the	non‐NRP	comparators	 (77%	vs.	16%,	P	<	.0001),	 and	
similarly	most	NRP	livers	were	retrieved	by	the	transplanting	center,	
unlike	 comparator	 livers	 (93%	 NRP	 vs.	 55%	 non‐NRP,	 P	<	.0001).	
While	the	median	withdrawal	period	was	slightly	shorter	in	the	NRP	
livers	(NRP	13	minutes,	non‐NRP	14	minutes,	P	=	.0707)	the	median	
asystolic	period	was	 slightly	 longer	 (NRP	16	minutes,	non‐NRP	13	
minutes,	P	<	.001)	 reflecting	 the	 extra	 time	 taken	 to	 establish	 the	
donor	on	the	extracorporeal	circuit.	NRP	was	performed	for	a	me‐
dian	of	123	minutes	(Figure	1).	As	a	consequence	of	distant	procure‐
ment	being	more	common	in	the	comparator	livers,	the	median	cold	
ischemic	times	experienced	by	the	comparator	livers	were	62	min‐
utes	longer	than	the	NRP	livers	(444	vs.	382	minutes,	P	=	.004).
3.2 | Recipient demographics and outcomes
The	liver	recipients	in	each	study	group	were	of	similar	age,	severity	of	
liver	disease	and	had	similar	 indications	for	transplantation	(Table	2).	
The	 incidence	of	early	 allograft	dysfunction,	defined	by	 the	Olthoff	
criteria,27	 was	 significantly	 lower	 in	 the	 NRP	 group	 (12%	 vs.	 32%,	
P	=	.0076),	 largely	 as	 a	 consequence	 of	 the	 significantly	 lower	 peak	
ALT	in	the	first	week	posttransplant	(633	iu/L	compared	to	1154	iu/L,	
P	<	.0001).	 Similarly,	 the	Model	 for	 Early	Allograft	 Function	 (MEAF)	
score	was	lower	in	NRP	treated	livers	(3.7	vs.	5.0,	P	<	.0001;	Figure	2).28 
Twelve	percent	of	the	comparator	livers	failed	within	the	first	30	days	
(7%	primary	nonfunction,	3%	hepatic	artery	thrombosis)	compared	to	
2%	of	NRP	livers	(hepatic	artery	thrombosis,	n	=	1)	(P	=	.0559).
Biliary	 complications	 were	 much	 more	 common	 in	 livers	 re‐
covered	without	NRP.	Of	the	171	non‐NRP	liver	recipients	whose	
livers	 lasted	more	 than	8	days,	26	 (15%)	developed	both	anasto‐
motic	strictures	and	ischemic	cholangiopathy,	21	(12%)	developed	
ischemic	 cholangiopathy	 alone,	 and	 21	 (12%)	 anastomotic	 stric‐
tures	 alone.	Where	NRP	was	used,	none	of	 the	 recovered	 livers	
developed	 cholangiopathy	 compared	 to	 a	 27%	 total	 incidence	
of	 cholangiopathy	 in	 non‐NRP	 livers	 (P	<	.0001).	 7%	of	 the	NRP	
DCD	livers	developed	an	anastomotic	stricture	compared	to	a	27%	
anastomotic	 stricture	 rate	 in	 the	 comparator	 group	 (P	=	.0069).	
The	actual	90‐day	death‐censored	graft	survival	and	patient	sur‐
vival	were	 comparable	between	groups,	 although	 the	5‐year	 ac‐
tuarial	 death‐censored	graft	 survival	was	 significantly	better	 for	
NRP	 livers	 (Figure	 3A,	 log	 rank	P	=	.0386).	 There	was	 no	 differ‐
ence	in	actuarial	patient	survival	or	graft	survival	not	censored	for	
death	with	a	functioning	graft	(Figure	3B,C).
Although	there	was	less	deterioration	in	renal	function	in	recip‐
ients	of	livers	recovered	using	NRP,	with	a	median	fall	in	estimated	
glomerular	filtration	rate	of	13	mls/min	compared	to	26	mls/min	in	
the	 non‐NRP	 liver	 recipients,	 the	 difference	 in	 CKD‐GFR	 did	 not	
reach	significance	(P	=	.6229;	Table	2).
3.3 | Factors determining ischemic cholangiopathy
Given	 the	 differences	 in	 donor	 and	 recipient	 populations	 in	 each	
group,	a	multivariate	analysis	was	undertaken	to	determine	whether	
NRP	was	a	significant	factor	in	preventing	ischemic	cholangiopathy	
(IC).
Tables	3‐5	 detail	 the	 recipient,	 donor	 and	 transplant	 factors	
considered.	Recipients	who	developed	cholangiopathy	had,	on	aver‐
age,	a	lower	serum	sodium	at	the	time	of	transplant.	Donors	whose	
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TA B L E  1  Donor	demographics	and	donation	data
Comparator cohort 
(n = 187)
NRP liver 
donors (n = 43)
NRP non‐liver 
donors (n = 27) P value
Age	(y)	(median;	IQR;	range) 50	(37‐58;	 
11‐76)
41	(33‐57;	
16‐69)
54	(38‐63;	
22‐78)
.1317
Cause	of	death,	n	(%)
Head	injury 23	(12%) 10	(23%) 5	(18%) .5358
Hypoxia 69	(37%) 12	(28%) 8	(30%)
Cerebrovascular	accident 90	(48%) 20	(47%) 13	(48%)
Other 5	(3%) 1	(2%) 1	(4%)
Agonal	period	(minutes)b	(median,	IQR) 14	(10‐18) 13	(11‐17) 18	(10‐89) .0707
Asystolic	period	(minutes)b 13	(11‐16) 16	(13‐20) 17	(13‐22) <.0001
Withdrawal	to	in	situ	perfusion	(minutes)b 27	(22‐32) 30	(26‐36) 34	(24‐108) .0046
Normothermic	regional	perfusion	duration	(minutes)c	(median;	IQR) 123	(103‐130) 122	(86‐127) .3657
Cold	ischemic	period	(minutes)d 444	(395‐493) 382	(303‐502) .0035
Preservation	period	(minutes)c 444	(395‐493) 510	(423‐631) .0008
US	donor	risk	indexc 2.5	(2.0‐2.9) 1.8	(1.7‐2.4) <.0001
UK	donor	liver	indexe 1.9	(1.6‐2.2) 1.9	(1.7‐2.2) 2.0	(1.8‐2.5) .4275
Location	of	donor <.0001
Local 29	(16%) 33	(77%) 18	(67%)
Regional 68	(36%) 10	(23%) 9	(33%)
National 90	(48%) 0	(0%) 0	(0%)
Proportion	of	occasions	the	transplanting	center	performed	the	
donor	organ	recovery
102	(55%) 40	(93%) <.0001
IQR,	interquartile	range;	NRP,	normothermic	regional	perfusion.
P	 values	 are	 for	 Kruskal‐Wallis	 test	 (continuous	 variables)	 and	 Fisher's	 exact	 test	 (categorical	 variables).	 Data	 are	 median	 (IQR)	 or	 number	
(percentage).
US	Donor	Risk	Index	from	Schaubel	et	al4;	Cold	ischemic	time	did	not	include	the	period	on	NRP.
Agonal	period:	from	withdrawal	of	life‐supporting	treatment	to	death.	Asystolic	period:	from	circulatory	arrest	to	in	situ	perfusion.	Normothermic	re‐
gional	perfusion:	from	restoration	of	circulation	to	the	abdominal	organs	to	cold	in	situ	perfusion.	Cold	ischemic	period:	from	in	situ	cold	perfusion	to	
reperfusion	in	recipient.	Preservation	period:	from	in	situ	perfusion	(cold	or	normothermic)	to	reperfusion	in	the	recipient.
aNot	reported	for	1	NRP	non‐liver	donor	and	2	non‐NRP	liver	donors.	
bNot	reported	for	1	NRP	non‐liver	donor	and	3	non‐NRP	liver	donors.	
cNot	reported	for	1	NRP	liver	donor.	
dNot	reported	for	3	non‐NRP	liver	donors.	
eUK	Donor	Liver	index	from	Collett	et	al3	A	liver	with	a	DLI	>1.31	is	in	the	upper	quartile	of	UK	donor	livers	and	has	a	3‐fold	higher	risk	of	graft	failure	
than	one	with	a	DLI≤1.31.
F I G U R E  1  Duration	of	NRP,	cold	
ischemia,	and	total	preservation.	NRP,	
normothermic	regional	perfusion
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recipients	developed	cholangiopathy	were	on	average	older,	had	a	
lower	peak	ALT	before	donation,	spent	 less	time	on	intensive	care	
prior	 to	donation,	were	not	 local	 to	 the	 recipient	center,	and	 their	
livers	were	recovered	without	using	NRP	compared	to	donors	whose	
recipients	did	not	develop	cholangiopathy.	Of	note,	neither	the	with‐
drawal	period,	the	asystolic	period,	nor	the	cold	ischemic	time	was	
associated	with	cholangiopathy	in	this	study,	probably	because	the	
variables	were	relatively	short	and	similar	in	each	group.
A	 logistic	 regression	model	was	then	built	 to	 identify	 the	odds	
of	 developing	 IC.	Donor	 age,	 the	 recipient	 sodium	 and	 locality	 of	
the	liver	predicted	the	development	of	IC	posttransplant	(Table	6).	
Although	NRP	was	highly	 significant	 (P	<	.0001)	 in	not	developing	
IC,	no	meaningful	odds	ratio	could	be	determined	since	there	were	
no	cases	of	IC	in	livers	from	donors	where	organ	recovery	used	NRP.
3.4 | Retrieval damage
Five	(11.6%)	of	the	NRP	livers	were	reported	to	be	damaged,	3	(7%)	
minor,	 2	 (4.7%)	moderate;	 48	 (25.7%)	 of	 the	 non‐NRP	 livers	were	
reported	to	be	damaged,	36	(19.3%)	minor	and	12	(6.4%)	moderate	
(P	=	.0689	for	any	damage;	P	=	.999	for	moderate	damage).
4  | DISCUSSION
This	paper	describes	our	experience	with	liver	transplantation	from	
controlled	DCD	donors	who	have	undergone	in	situ	normothermic	
regional	perfusion	(NRP)	before	organ	recovery,	and	compares	those	
cases	to	a	contemporaneous	cohort	of	 liver	transplants	from	DCD	
donors	who	did	not	undergo	NRP	but	were	also	transplanted	in	the	
two	study	centers.	The	study	has	shown	that	NRP	is	an	independent	
factor	in	reducing	the	incidence	of	ischemic	cholangiopathy	in	DCD	
livers	 following	 transplantation,	 so	 much	 so	 that	 no	 liver	 from	 a	
donor	undergoing	NRP	prior	to	recovery	developed	cholangiopathy.	
Our	study	has	also	shown	that	 lower	 recipient	sodium	at	 the	time	
of	surgery,	older	donor	age,	and	a	donor	outside	the	local	hospital	
was	 independently	 associated	 with	 the	 development	 of	 ischemic	
cholangiopathy.
The	study	is	limited	by	being	a	retrospective	analysis	of	prospec‐
tively	collected	data,	rather	than	being	a	randomized	controlled	trial.	
We	have	compensated	for	this	by	including	a	contemporaneous	com‐
parator	group	of	all	the	DCD	livers	transplanted	in	the	study	centers	
over	the	same	7‐year	study	period.	The	regression	analysis	that	we	
undertook	allowed	for	other	potentially	confounding	factors	where	
the	two	groups	differed,	such	as	the	variations	in	cold	ischemic	time	
and	locality	of	the	donor,	to	be	taken	into	account	when	determining	
that	NRP	was	an	independent	factor	in	the	nonoccurrence	of	chol‐
angiopathy.	Differences	in	donor	age,	cold	ischemic	time,	and	local‐
ity	contributed	to	the	difference	in	US	DRI	between	groups,	which	
favored	the	NRP	livers;	neither	locality	nor	CIT	contribute	to	the	UK	
Donor	Liver	Index	which	showed	the	two	groups	to	be	similar.	The	
supplementary	data	illustrate	that	even	at	the	extremes	of	donor	age,	
CIT	and	withdrawal	time,	NRP	appears	superior.	The	other	limitation	
is	in	the	identification	of	the	endpoint,	given	that	not	every	patient	
underwent	cholangiography.	Although	none	of	the	NRP	group	had	
cholangiopathy	detected,	31%	of	the	NRP	group	had	cholangiograms	
performed	which	did	not	show	a	cholangiopathy	compared	to	25%	
in	 the	non‐NRP	group	 that	 showed	no	cholangiopathy,	 suggesting	
that	there	was	no	bias	in	investigating	for	possible	cholangiopathy.	
This	is	in	addition	to	the	27%	of	non‐NRP	patients	who	had	positive	
cholangiograms.	The	apparently	high	incidence	of	cholangiopathy	in	
the	non‐NRP	arm	is	similar	to	the	26.3%	incidence	seen	in	the	DCD	
livers	 in	 the	 control	 group	 of	 a	 recently	 published	 normothermic	
machine	perfusion	(NMP)	study.	Moreover,	the	absence	of	cholangi‐
opathy	with	NRP	contrasts	with	the	11.1%	incidence	in	DCD	livers	
undergoing	NMP	from	the	point	of	retrieval	at	the	donor	hospital.8 
This	suggests	that	NRP	in	DCD	liver	donors	may	be	superior	to	NMP	
in	 the	prevention	of	biliary	complications,	an	observation	 that	will	
need	further	exploration;	other	observations	also	suggest	that	NMP	
does	not	protect	DCD	livers	from	cholangiopathy.29
Our	 cholangiopathy	 data	 mirror	 the	 Spanish	 experience	 pre‐
sented	 at	 the	 2018	 International	 Liver	 Transplantation	 Society	
Congress,	where	they	described	a	2%	incidence	of	cholangiopathy	in	
95	cases	of	NRP	compared	to	12%	in	124	conventionally	recovered	
DCD	livers;	1	year	graft	survival	was	also	not	significantly	better	in	
that	 study	 also	 (87%	NRP,	 78%	 non‐NRP).30	 Assuming	 the	 appar‐
ent	difference	 in	cholangiopathy	rates	 is	 real,	and	the	presence	of	
similar	results	from	the	Spanish	series	suggests,	 it	 is	 interesting	to	
speculate	what	may	have	contributed	to	it.	One	theory	of	cholangi‐
opathy	in	DCD	livers	suggests	the	etiology	to	be	related	to	ischemia	
of	the	bile	ducts	and	the	possible	presence	of	thrombi	in	the	biliary	
plexus.31,32	Restoration	of	a	heparinized	circulation	may	hasten	their	
dispersal,	and	there	is	some	evidence	that	DCD	donors	exhibit	fibri‐
nolysis	during	NRP,	which	may	contribute.33	However,	a	high	rate	of	
F I G U R E  2  Box	and	whisker	plot	showing	difference	in	model	for	
early	allograft	function	(MEAF)	score	between	groups
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F I G U R E  3  Kaplan	Meier	plots	showing	
(A)	death‐censored	graft	survival,	
(B)	patient	survival,	and	(C)	graft	survival	
where	deaths	with	functioning	grafts	
were	treated	as	graft	loss
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TA B L E  2  Recipient	demographics	and	outcomes
NRP,  
n = 43
Comparator cohort, 
n = 187 P value
Recipient	age	(median,	IQR,	range) 60	(51‐64;	34‐73) 57	(51‐63;	18‐72) .3192
Liver	disease	necessitating	transplant
Alcohol	related	liver	disease 8	(19%) 41	(22%) .6155
Hepatocellular	carcinoma 17	(39%) 67	(36%)
Hepatitis	C	cirrhosis 2	(5%) 13	(7%)
Primary	sclerosing	cholangitis 3	(7%) 15	(8%)
Primary	biliary	cholangitis 6	(14%) 22	(12%)
Nonalcoholic	fatty	liver	disease	(NAFLD) 4	(9%) 12	(6%)
Retransplant 2	(5%) 2	(1%)
Other 1	(2%) 15	(8%)
UKELD	at	transplant	(median	[IQR])a 56	(52‐59) 54	(50‐58) .2389
MELD	at	transplant	(median	[IQR])c 15	(12‐23) 15	(11‐20) .4169
Peak	ALT	in	first	7	d	(median	[IQR]) 633	(319‐1070) 1154	(667‐2099) <.0001
Early	allograft	dysfunctionc 5/43	(12%) 55/173	(32%) .0076
Model	for	early	allograft	function	(median	[IQR])f 3.5	(2.4‐5.1) 5.0	(3.8‐6.6) <.0001
Bile	duct	complicationsd
Biliary	leak 3/43	(7%) 18/174	(10%) .7731
Anastomotic	stricture 3/42	(7%) 46/171	(27%) .0041
Ischemic	cholangiopathy 0/42	(0%) 47/171	(27%) <.0001
Proportion	undergoing	cholangiography	(M/ERCP) 13/42	(31%) 91/171	(53%) .0102
Graft	loss
Primary nonfunction 0 13	(7%)e .1347
Hepatic	artery	thrombosis	in	first	28	d 1	(2%) 5	(3%) >.99
Ischemic	cholangiopathy 0 11	(6%) .2253
Other 0 2	(1%) >.99
Graft	survival	at	90	days	%	(95%	CI)	(deaths	with	a	functioning	graft	
censored)
97.7	(84.6,	99.7) 89.8	(84.5,	93.4) .1019
Graft	survival	at	90	days	%	(95%	CI)	(deaths	with	a	functioning	graft	
classed	as	events)
97.7	(84.6,	99.7) 88.8	(83.3,	92.1) .0760
Patient	survival	at	90	days	%	(95%	CI) 100	(‐) 97.3%	(93.7,	98.9) .2810
CKD‐Epi	GFR	mls/min/1.73	m2	(median,	IQR) .6229
Baseline	(n	=	43/43;	187/187) 84	(64‐100) 95	(73‐105)
1	mo	(n	=	43/43;	177/182) 70	(52‐87) 77	(53‐97)
2	mo	(n	=	42/42;	173/182) 65	(46‐81) 73	(55‐91)
3	mo	(n	=	41/42;	161/181) 63	(50‐75) 69	(52‐85)
4	mo	(n	=	36/42;	165/180) 62	(52‐77) 68	(53‐85)
6	mo	(n	=	40/40;	160/176) 67	(54‐87) 72	(55‐89)
12	mo	(n	=	38/39;	163/166) 72	(53‐84) 70	(52‐87)
P‐values	are	for	Kruskal‐Wallis	test	(continuous	variables)	and	Fisher's	exact	test	(categorical	variables).	Tests	not	performed	for	graft	failures	or	deaths.
Analysis	of	variance	(ANOVA)	was	used	to	compare	CKD‐Epi	GFR	over	time	and	between	the	two	groups.	A	random	effect	was	included	in	the	model	
to	allow	for	correlation	between	GFR	at	different	time	points	for	the	same	patient.	Data	are	median	(IQR)	or	number	(percentage).
aUKELD	=	United	Kingdom	end‐stage	liver	disease	score.39	A	UKELD	of	≥49	corresponds	to	a	survival	benefit	in	favor	of	transplantation.	UKELD	not	
available	for	one	NRP	liver	and	two	non‐NRP	livers.	
bMELD	=	Model	for	End‐stage	Liver	Disease.40 
cEarly	allograft	dysfunction	defined	as	ALT	>	2000	u/L	in	first	week,	or	INR	≥	1.6	or	Bilirubin	≥171	μmol/L	on	day	7.27	Excludes	14	grafts	lost	in	first	
week	in	comparator	cohort	due	to	primary	nonfunction,	hepatic	artery	thrombosis	or	death,	and	one	in	NRP	cohort	with	hepatic	artery	thrombosis.	
dDenominators	exclude	livers	with	early	failure	from	consideration	for	anastomotic	stricture	or	ischemic	cholangiopathy.	
eIncludes	2	patients	dying	from	PNF	without	a	retransplant.	
fModel	for	early	allograft	function.28	Data	not	available	for	two	patients	in	NRP	group,	and	for	eight	patients	in	non‐NRP	group	including	four	with	PNF.	
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cholangiopathy	has	been	reported	in	controlled	DCD	livers	receiving	
ante‐mortem	heparinization	and	undergoing	“super‐rapid	recovery,”	
where	thrombi	should	not	be	forming.30	It	is	also	possible	that	bile	
ducts	are	more	sensitive	to	ischemia	than	hepatocytes,	with	less	re‐
generative	capacity,	and	benefit	most	from	early	reperfusion	in	the	
donor	 and	avoidance	of	 consecutive	periods	of	warm	 followed	by	
cold	ischemia.
Another	possible	explanation	for	the	absence	in	cholangiopathy	
relates	to	the	composition	of	the	bile.	Treatment	withdrawal	in	the	
donor	is	followed	by	a	period	of	reduced	organ	perfusion	secondary	
to	 catecholamine	 release	 in	 response	 to	 falling	 systemic	 pressure	
and	cerebral	perfusion.5	With	decreasing	perfusion,	and	decreasing	
oxygenation,	the	donor	becomes	more	acidotic,	and	the	ability	of	the	
cholangiocytes	to	produce	bicarbonate	may	be	impaired.	By	restor‐
ing	a	circulation	promptly	following	arrest	it	is	possible	that	the	bili‐
ary	tree	has	time	to	recover	and	produce	the	bicarbonate	“umbrella”	
that	has	been	proposed	to	stop	direct	bile	salt	 injury	of	the	biliary	
epithelium.34,35
Several	 additional	 observations	 are	 noteworthy.	 The	 non‐NRP	
livers	suffered	a	numerically	higher	(7%)	incidence	of	primary	non‐
function,	 compared	 to	 no	 primary	 nonfunction	 in	 the	 NRP	 livers	
(P	=	.1347).	This	is	in	spite	of	the	liver	utilization	rate	in	NRP‐treated	
livers	being	61%,	 in	contrast	 to	 the	UK	national	 rate	without	NRP	
which	 varied	 between	 27%	 and	 36%	 per	 annum	 in	 the	 period	 of	
the	 study,1,36	 suggesting	 that	 selection	 bias	was	 probably	 not	 the	
reason	for	the	better	initial	outcomes.	Instead	the	difference,	albeit	
not	 significant	 in	 this	 small	 study,	was	 probably	 accounted	 for	 by	
the	ability	to	test	liver	viability	and	function	in	the	period	after	the	
warm	ischemic	insults	that	characterize	the	withdrawal	and	asystolic	
periods.5,6
The	ability	to	test	viability	of	the	liver	in	situ	is	the	main	benefit	
of	NRP.	Our	small	series	does	not	provide	sufficient	information	to	
define	viability	criteria,	but	we	followed	similar	parameters	to	those	
published	to	help	assess	uncontrolled	DCD	donors	in	Spain,20 namely 
lactate	fall	as	a	marker	of	function	and	ALT	release	as	a	marker	of	
damage,	although	we	adopted	a	more	 liberal	 interpretation	of	ALT	
levels	to	inform	liver	utilization.	It	is	likely	that	with	more	experience	
clear	parameters	will	be	defined.
Three	livers	were	lost	in	settings	where	they	may	have	been	uti‐
lized	if	NRP	had	not	been	performed.	In	one	case,	there	was	severe	
aortic	atheroma	and	a	nonfunctioning	shrunken	left	kidney	second‐
ary	to	ostial	atheroma.	During	NRP,	atheromatous	emboli	occluded	
the	origin	of	the	celiac	trunk	and	right	renal	ostium,	something	that	
may	not	have	happened	if	retrograde	cold	perfusion	had	been	used	
from	 the	 start.	 In	 two	other	 cases	clots	were	noted	 in	 the	circuit,	
in	one	case	associated	with	the	leucocyte	filter	and	in	the	other	in	
TA B L E  3  Summary	of	recipient	and	donor	continuous	variables	and	their	association	with	ischemic	cholangiopathy	for	the	231	DCD	
donor livers transplanted
Continuous variable
Ischemic cholangiopathy
Total (n = 230)Yes (n = 47) No (n = 183)
P‐valueNo missing Median (IQR) No missing Median (IQR) No missing Median (IQR)
Recipient factors
Age	(y) 0 58	(54‐62) 0 57	(51‐63) 0.9 0 57	(51‐63)
Creatinine	(μmol/L) 0 69	(56‐89) 0 74	(63‐95) 0.2 0 73	(62‐95)
Bilirubin	(μmol/L) 0 46	(30‐83) 0 43	(20‐88) 0.5 0 43.5	(22‐86)
International	normal‐
ised	ratio	(INR)
0 1.4	(1.2‐1.6) 0 1.4	(1.14‐1.6) 0.7 0 1.4	(1.14‐1.6)
Sodium	(mmol/L) 0 135	(132‐138) 0 137	(134‐139) 0.01 0 136	(134‐139)
Potassium	(mmol/L) 1 4.2	(4‐4.5) 2 4.1	(3.9‐4.5) 0.6 3 4.1	(3.9‐4.5)
Albumin	(gm/L) 1 29	(25‐34) 1 29	(25‐33) 0.6 2 29	(25‐34)
Waiting	time	to	
transplant	(d)
0 94	(23‐248) 4 74	(28‐183) 0.4 4 77.5	(26‐193)
Donor	factors
Donor	age	(y) 0 52	(45‐63) 0 48	(35‐58) 0.02 0 49	(36‐58)
Donor	BMI	(kg/m2) 0 25.8	
(22.3‐28.3)
0 25.7	 
(22.9‐28.3)
0.96 0 25.7	
(22.8‐28.3)
Donor	height	(cm) 0 172	(167‐177) 0 172	(165‐179) 0.97 0 172	(165‐178)
Maximum	ALT	(iu/L) 0 29	(20‐55) 4 40	(22‐84) 0.04 4 36	(21‐73)
Maximum	bilirubin	
(μmol/L)
0 9	(6‐12) 0 9	(6‐14) 0.4 0 9	(6‐14)
ITU	stay	(d) 0 2	(1‐4) 2 3	(2‐5) 0.04 2 3	(2‐5)
Hospital	stay	prior	to	
donation	(d)
0 3	(1‐5) 0 3	(2‐5) 0.12 0 3	(2‐5)
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the	 reservoir.	 Both	 cases	 were	 in	 conjunction	 with	 thoracic	 can‐
nulation	for	recovery	of	the	heart.	The	etiology	of	the	clots	 is	un‐
clear,	but	their	occurrence	suggests	inadequate	mixing	of	returning	
blood	with	heparin	before	reaching	thrombogenic	surfaces	such	as	
the	leucocyte	filter,	oxygenator	or	particulate	filter	in	the	reservoir.	
In	 the	original	Cambridge	series,	a	shunt	was	used	to	divert	blood	
away	from	the	oxygenator	for	a	few	minutes	until	adequate	mixing	
of	 the	 blood	with	 the	 heparinized	 prime	 solution	 had	 occurred,10 
while	Edinburgh	also	used	heparin‐coated	components	in	its	circuit.	
In	 the	 current	 circuit	 only	 the	 leucocyte	 filter	 is	 bypassed	 for	 the	
first	2	minutes	of	perfusion.	Ensuring	adequate	heparinization	at	the	
start	of	NRP	is	paramount	if	clots	and	emboli	are	to	be	avoided,	and	
this	may	be	best	achieved	by	premortem	heparinization	in	countries	
where	this	is	permitted.
NRP	has	other	benefits,	and	in	this	series	it	was	used	to	facilitate	
DCD	heart	transplantation.37	We	have	also	been	able	to	use	livers	
with	 longer	 withdrawal	 periods	 than	 currently	 accepted	 by	 many	
centers,38	reassured	by	the	knowledge	that	the	liver's	function	can	
Variable Level
Ischemic cholangiopathy Fishers exact 
P‐valueYes (N = 47) No (N = 183)
Sex Male 31	(66.0%) 119	(65%) >.99
Female 16	(34%) 64	(35.0%)
Disease	group Alcohol	related	liver	
disease
14	(29.8%) 35	(19.1%) .9
HCC 15	(31.9%) 69	(37.7%)
HCV 2	(4.3%) 13	(7.1%)
Primary	sclerosing	
cholangitis
4	(8.5%) 14	(7.7%)
Primary	biliary	
cholangitis
6	(12.8%) 22	(12.0%)
NAFLD 2	(4.3%) 14	(7.7%)
Retransplant 0	(0%) 4	(2.2%)
Other 4	(8.5%) 12	(6.6%)
HCV	status No	HCV 38	(80.9%) 136	(74.3%) .4
HCV 9	(19.1%) 47	(25.7%)
Renal support Hemodialysis 1	(2.1%) 13	(7.1%) .6
Hemofiltration 0	(0%) 2	(1.1%)
Not	required 46	(97.9%) 166	(91.8%)
Inpatient	status Out‐patient 39	(83.0%) 155	(84.7%) .8
In‐patient 8	(17.0%) 28	(15.3%)
Previous 
abdominal	
surgery
No 43	(91.5%) 158	(86.3%) .5
Yes 4	(8.5%) 25	(13.7%)
Encephalopathy Not	present 30	(63.8%) 137	(74.9%) .18
Compromised; 
altered	mood/
behavior;	
psychometric	
defects
16	(34%) 39	(21.3%)
Drowsy;	inappropri‐
ate	behavior
0	(0%) 5	(2.7%)
Coma;	cannot	be	
aroused
0	(0%) 1	(0.5%)
Unknown 1	(2.2%) 1	(0.5%)
Ascites No	ascites 24	(51.1%) 102	(55.7%) .6
Ascites 23	(48.9%) 81	(44.3%)
Diabetes No 33	(70.2%) 126	(68.9%) .9
Yes 14	(29.8%) 53	(29.0%)
Not	reported 0	(0%) 4	(2.2%)
TA B L E  4  Summary	of	categorical	
recipient	factors	for	231	DCD	donor	livers	
transplanted	by	ischemic	cholangiopathy
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TA B L E  5  Summary	of	categorical	donor	and	transplant	related	variables	for	231	DCD	donor	livers
Categorical variable Level
Ischemic cholangiopathy Fishers exact 
P‐valueYes (n = 47) No (n = 183)
Donor	grouped	cause	
of	death
Head	injury 5	(10.6%) 28	(15.3%) .4
Hypoxia 13	(27.7%) 68	(37.2%)
CVA 28	(59.6%) 82	(44.8%)
Other 1	(2.1%) 5	(2.7%)
Donor	sex Male 28	(59.6%) 110	(60.1%) >.99
Female 19	(40.4%) 73	(39.9%)
Donor	ethnicity White 46	(97.9%) 177	(96.7%) >.99
Asian 1	(2.1%) 6	(3.3%)
History	of	diabetes No 45	(95.7%) 174	(95.1%) >.99
Yes 2	(4.3%) 8	(4.4%)
Unknown 0	(0%) 1	(0.5%)
History	of	smoking No 23	(48.9%) 99	(54.1%) .6
Yes 24	(51.1%) 84	(45.9%)
Organ	appearance Healthy 35	(74.5%) 147	(80.3%) .4
Suboptimal 12	(25.5%) 33	(18%)
Unknown 0	(0%) 3	(1.6%)
Steatosis No 27	(57.4%) 113	(61.7%) .8
Yes 20	(42.6%) 67	(36.6%)
Unknown 0	(0%) 3	(1.6%)
Steatosis	degree No 27	(57.4%) 113	(61.7%) .4
Yes,	mild 12	(25.5%) 46	(25.1%)
Yes,	moderate 7	(14.9%) 21	(11.5%)
Yes,	severe 1	(2.1%) 0	(0%)
Unknown 0	(0%) 3	(1.6%)
Normal	anatomy No 16	(34.0%) 50	(27.3%) .5
Yes 30	(63.8%) 130	(71%)
Unknown 1	(2.1%) 3	(1.6%)
Grade	of	retrieval	
damage
None 40	(85.1%) 150	(82.0%) .9
Mild 3	(6.4%) 18	(9.8%)
Moderate 2	(4.3%) 6	(3.3%)
Unknown 2	(4.3%) 9	(4.9%)
Retrieval team A 2	(4.3%) 10	(5.5%) .11
B 7	(14.9%) 15	(8.2%)
C 7	(14.9%) 8	(4.4%)
D 0	(0%) 6	(3.3%)
E 13	(27.7%) 72	(39.3%)
F 5	(10.6%) 21	(11.5%)
G 13	(27.7%) 51	(27.9%)
Donation	year 2011 8	(17.0%) 20	(10.9%) .5
2012 4	(8.5%) 21	(11.5%)
2013 6	(12.8%) 22	(12.0%)
2014 7	(14.9%) 32	(17.5%)
2015 13	(27.7%) 32	(17.5%)
2016 7	(14.9%) 40	(21.9%)
2017 2	(4.3%) 16	(8.7%)
(Continues)
12  |     WATSON eT Al.
be	checked	in	situ	before	removal.	This	further	increases	the	avail‐
able	pool	of	DCD	donor	livers	that	may	be	used	to	address	the	high	
mortality	of	those	on	the	waiting	list.	The	functional	assessment	also	
allows	for	the	discard	of	 livers	that	may	develop	primary	nonfunc‐
tion	 but	which	 previously	would	 have	 been	 used	 based	 solely	 on	
predonation data.
In	 summary,	 we	 have	 described	 43	 cases	 of	 liver	 transplanta‐
tion	from	DCD	donors	subject	to	NRP,	with	improved	early	allograft	
function,	 absence	of	 ischemic	 cholangiopathy,	 and	 improved	 graft	
survival.	The	multivariate	analysis	emphasizes	the	potential	of	NRP	
as	an	 independent	 factor	preventing	 ischemic	cholangiopathy,	and	
the	study	supports	continued	implementation	and	evaluation	of	the	
technique.
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TA B L E  6  Summary	of	continuous	transplant	related	factors	for	DCD	donor	liver	transplants,	by	ischemic	cholangiopathy
Variable
Ischemic cholangiopathy
Total (n = 230)Yes (n = 47) No (n = 183)
P‐valueNo missing Median (IQR) No missing Median (IQR) No missing Median (IQR)
Asystolic	perioda 1 14	(12‐16) 0 13	(11‐16) 0.4 0 13	(11‐16)
Withdrawal	period	
(min)b
0 28	(22‐32) 2 28	(23‐33) 0.7 0 28	(22‐33)
Cold	ischaemia	
time	(min)
0 428	(385‐477) 2 438	(382‐499) 0.94 0 433.5	(383‐496.5)
aAsystolic	period:	circulatory	arrest	to	in	situ	cold	perfusion	with	preservation	solution	or	commencement	of	NRP.	
bWithdrawal	period,	from	withdrawal	of	treatment	to	circulatory	arrest.	
TA B L E  7  Logistic	regression	model	for	odds	of	developing	
ischemic	cholangiopathy
Factor Level N
Odds ratio 
(95% CI) P‐value
Donor	age	(y) Linear 207 1.03	(1.00,	
1.06)
.015
Recipient sodium at 
transplant	(mmol/L)
Linear 207 0.90	(0.83,	
0.98)
.02
Locality	of	liver Local 58 0.31	(0.11,	
0.93)
.03
Regional 68 1.00
National 81 1.09	(0.51,	
2.32)
CI,	confidence	interval;	NRP,	Normothermic	regional	perfusion.
NRP	 use	 was	 statistically	 significant	 after	 adjusting	 for	 other	 factors	
(P	=	.0001).	However,	we	were	not	able	to	produce	meaningful	odds	ra‐
tios	as	there	were	no	cases	of	ischemic	cholangiopathy	in	the	NRP	group.
Categorical variable Level
Ischemic cholangiopathy Fishers exact 
P‐valueYes (n = 47) No (n = 183)
Locality	of	donor Local 6	(12.8%) 56	(30.6%) .03
Regional 17	(36.2%) 61	(33.3%)
National 24	(51.1%) 66	(36.1%)
Blood	group	
compatibility
Identical 46	(97.9%) 181	(98.9%) .5
Compatible 1	(2.1%) 2	(1.1%)
Perfusion used Comparator 47	(100%) 140	(76.5%) <.0001
NRP 0	(0%) 43	(23.5%)
TA B L E  5   (Continued)
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